18 completed. 18 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 18 |
| Phase 2 | 4 | Completed 4 |
Follow Interferon alpha-2: new trials by email Literature Review of Interferon alpha-2 trials Research Report on Interferon alpha-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis Interferon Alfa-2A, Cyclosporine Pill - Behçet Disease, Uveitis | Phase 3 | Completed | Peking Union Medical College Hospital | 28 | 2017-06-30 | 2021-02-23 |
| Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders interferon alfa-2b - Chronic Hepatitis C | Phase 2 / Phase 3 | Completed | Foundation for Liver Research | 30 | 2007-07-01 | 2011-03-11 |
| Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB) Cyclosporin A, Interferon-alpha2a - Behcet's Disease, Panuveitis | Phase 3 | Completed | University Hospital Tuebingen | 37 | 2004-11-01 | 2018-05-17 |
| Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB pegylated interferon-alpha-2a, interferon-alpha-2a - Melanoma | Phase 3 | Completed | University Hospital Tuebingen | 901 | 2004-10-01 | 2017-05-03 |
| SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma Interferon-alfa, SU011248 - Carcinoma, Renal Cell | Phase 3 | Completed | Pfizer | 750 | 2004-08-01 | 2010-01-26 |
| A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy Bevacizumab [Avastin], Interferon alfa 2a [Roferon], Placebo - Renal Cell Cancer | Phase 3 | Completed | Hoffmann-La Roche | 649 | 2004-06-01 | 2016-06-23 |
| A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies Pegylated Interferon Alfa-2a, Recombinant Interferon Alfa 2a - Chronic Myelogenous Leukemia, Malignant Melanoma | Phase 2 / Phase 3 | Completed | Hoffmann-La Roche | 9 | 2004-01-01 | 2017-01-09 |
| High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) Gleevec, Peg-alpha interferon (Peg-Intron), Sargramostim (GM-CSF) - Leukemia, Myeloid, Chronic | Phase 3 | Completed | M.D. Anderson Cancer Center | 94 | 2003-04-01 | 2016-05-11 |
| High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV Peginterferon alfa-2a, Interferon alfa-2a, Ribavirin - Hepatitis C | Phase 3 | Completed | Foundation for Liver Research | 33 | 2003-02-01 | 2021-09-01 |
| A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma rituximab, interferon-a-2a - Lymphoma | Phase 3 | Completed | Hoffmann-La Roche | 313 | 2002-10-01 | 2014-09-08 |
| Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma Dacarbazine, Fotemustine, Interferon Alfa-2b - Malignant Melanoma, Recurrent Melanoma | Phase 3 | Completed | National Cancer Institute, Naples | 269 | 2002-04-01 | 2023-04-11 |
| High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma interferon alfa-2b, observation - Melanoma (Skin) | Phase 3 | Completed | ECOG-ACRIN Cancer Research Group | 1150 | 1999-03-25 | 2026-09-29 |
| Interferon Alpha 2b Plus Ribavirin for Chronic Hepatitis B interferon alpha 2b plus ribavirin, interferon alpha 2b plus placebo - Chronic Hepatitis B | Phase 2 / Phase 3 | Completed | National Taiwan University Hospital | 120 | 1998-10-01 | 2006-01-12 |
| Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016) PEG-Intron, Interferon Alfa-2B - Hepatitis C | Phase 2 / Phase 3 | Completed | Merck Sharp & Dohme LLC | 1224 | 1997-08-05 | 2019-04-09 |
| Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma Aldesleukin (IL-2), Recombinant Interferon Alfa (IFN-A), Cisplatin - Melanoma, Skin Cancer | Phase 3 | Completed | M.D. Anderson Cancer Center | 140 | 1995-11-01 | 2011-12-13 |
| Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III interferon alpha 2a - Leukemia, Lymphocytic, Acute | Phase 3 | Completed | French Innovative Leukemia Organisation | 232 | 1994-09-01 | 2007-06-06 |
| Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma. Interferon Alfa-2a, Interleukin-2 - Carcinoma, Renal Cell | Phase 3 | Completed | Gruppo Oncologico Italiano di Ricerca Clinica | 310 | 1994-07-01 | 2013-07-10 |
| Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer aldesleukin, recombinant interferon alpha-2a, medroxyprogesterone - Kidney Cancer | Phase 3 | Completed | Centre Leon Berard | 456 | 2012-09-26 |
Carcinoma, Renal Cell (5) · Melanoma (5) · Behcet Syndrome (2) · Hepatitis C (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Hepatitis B (1) · Hepatitis B, Chronic (1) · Hepatitis C, Chronic (1) · Kidney Neoplasms (1) · Leukemia, Myeloid, Chronic-Phase (1) · Lymphoma (1) · Panuveitis (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Retinal Vasculitis (1) · Skin Neoplasms (1)
Hoffmann-La Roche (3) · Foundation for Liver Research (2) · M.D. Anderson Cancer Center (2) · University Hospital Tuebingen (2) · Centre Leon Berard (1) · ECOG-ACRIN Cancer Research Group (1) · French Innovative Leukemia Organisation (1) · Gruppo Oncologico Italiano di Ricerca Clinica (1) · Merck Sharp & Dohme LLC (1) · National Cancer Institute, Naples (1) · National Taiwan University Hospital (1) · Peking Union Medical College Hospital (1) · Pfizer (1)
Germany (4) · United States (4) · Australia (3) · Canada (3) · France (3) · Italy (3) · Netherlands (3) · Russia (3) · Spain (3) · Norway (2) · Poland (2) · South Africa (2) · United Kingdom (2) · Belgium (1) · Brazil (1)
Agop Y. Bedikian, MD (1) · Alberto S. Pappo, MD (1) · Antonio Daponte, M.D. (1) · Carlo Buzio, Medicine (1) · Claus Garbe, MD (1) · Hubert Pehamberger, MD (1) · Ina Koetter, MD (1) · John M. Kirkwood, MD (1) · Jorge E Cortes, MD (1) · Lawrence E. Flaherty, MD (1) · Michael Smylie, MD, MB, ChB (1) · Ming-Yang Lai, Professor (1)
PMID 15256423, PMID 17215529, PMID 17932908, PMID 19430405, PMID 20104222, PMID 23402397, PMID 23620574, PMID 25304727, PMID 25577718, PMID 25686644, PMID 27238653, PMID 27287206, PMID 28410911, PMID 28835440, PMID 29853320, PMID 30885996, PMID 37146227
2004 (2), P30CA016672 (1), U10CA023318 (1)